Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21634694 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL24392030 | 0.85 | USP2 (0.39) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL731836 | 0.84 | GPR119 (0.43) | USP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL5765972 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL29161080 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL1475092 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2GPR119 | |
| SCHEMBL22557616 | 0.81 | CYP1A2 (0.34) | USP2SMN1; SMN2EPHX2 | |
| SCHEMBL23780520 | 0.81 | APP (0.33) | — | |
| SCHEMBL15368820 | 0.81 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL13805598 | 0.81 | GPR119 (0.42) | USP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250326721-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| WO-2007092095-A2 | [4-(BENZO [B] THI0PHEN-2-YL) PYRIMIDIN-2YL] -AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES. | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-09-28 | — | — | US | disclosed |
| WO-2006056873-A2 | THERAPEUTIC PYRAZOLO[3,4-B] PYRIDINES AND INDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-06-01 | — | — | US | disclosed |
| US-6995144-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | USP2 730/4885SMN1; SMN2 3384/4885GPR119 192/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | USP2 635/4885SMN1; SMN2 3927/4885GPR119 53/4885 |
| US-20250326721-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | USP2 4321/4885SMN1; SMN2 315/4885GPR119 649/4885 |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | USP2 3928/4885SMN1; SMN2 1175/4885GPR119 832/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | USP2 2551/4885SMN1; SMN2 1226/4885GPR119 1037/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | USP2 4672/4885SMN1; SMN2 4744/4885GPR119 601/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | USP2 4747/4885SMN1; SMN2 4599/4885GPR119 445/4885 |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | P2RX3, P2RX4, ACHE | USP2 3597/4885SMN1; SMN2 314/4885GPR119 226/4885 |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | P2RX3, P2RX4, ACHE | USP2 3597/4885SMN1; SMN2 314/4885GPR119 226/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | USP2 3522/4885SMN1; SMN2 1325/4885GPR119 1520/4885 |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | USP2 3639/4885SMN1; SMN2 1451/4885GPR119 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.